“[AMR] is an increasingly serious threat to global public health that requires action across all government sectors and society.” - World Health Organization
It is an alarming fact that AMR (AntiMicrobial Resistance) claims 23,000 Americans lives each year. According to a report commissioned by British Prime Minister David Cameron, AMR could result in 10 million deaths a year by 2050 at a cost of $100 trillion to the global economy.
How do we combat this global threat? One of the key things is to develop new antibiotics.
Whilst there are a number of scientific and big policy conferences in the world, there are only a few that focus on the economic side. Still, none of the conferences explore other alternatives to the PPP model for developing antibiotics and none talk about vaccines, for instance, for infection prevention.
Are there other innovative and alternative ways to public-private partnerships? How can developing new antibiotics make more business sense? How can the GAIN Act be improved? Are there other incentives under way? Have infection prevention such as new vaccines been considered? Are there other ground-breaking technologies to aid in diagnosis, surveillance and prevention?
Announcing the launch of the World AntiMicrobial Resistance Congress, which will gather key stakeholders from government, funding agencies, pharma, academia and payers to discuss this urgent need for new antibiotics. President Obama has outlined his 5-year action plan to fight AMR and is seeking to double the AMR funding to $1.2B, but the bigger challenge is how to deliver these actions.
Speakers already confirmed include:
Jane Knisely, Program Officer, Bacteriology & Mycology Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Disease, NIH
Jane oversees scientific programs related to antimicrobial resistance and antibacterial drug development. Specifically, she is the Program Officer for the Antibacterial Resistance Leadership Group. She is a member of both the Interagency and the Trans-Atlantic Task Forces on Antimicrobial Resistance.
Dr. Rosemarie Aurigemma, Chief, Drug Development Section, Office of Biodefense Research Resources and Translational Research, NIAID, NIH
Dr. Aurigemma directs the advancement of new therapies for existing and emerging infectious diseases important to public health such as influenza, antibiotic resistant infections, and dengue fever, as well as for infectious bioterrorism agents, such as anthrax. The work supported under her group has resulted in advancement of valuable new products for treating anthrax, pandemic flu, botulism and drug resistant bacterial infections. Dr. Aurigemma collaborates with other federal agencies within the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) including the CDC, FDA, DoD, BARDA and DHS. In this role, she contributes to the establishment of policies and practices for meeting the nation’s emergency medical countermeasure needs. In 2014, Dr. Aurigemma’s group was responsible for gathering pivotal study data to advance promising drugs to treat Ebola Virus Disease. Dr. Aurigemma has also collaborated with federal colleagues on drafting the action plan to meet the objectives of the Combating Antibiotic Resistant Bacteria (CARB) initiative.
Melissa Stundick, Chief, Broad Spectrum Antimicrobials Program, Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services (DHHS)
Melissa oversees a portfolio of approximately $1.2B in procurement and advanced research and development contracts which support the development of novel antibacterial and antiviral drugs. Prior to joining BARDA in 2011, Dr. Stundick provided scientific and program management support as a Contractor to a number of Government and private entities, including the Department of Defense, Department of Homeland Security, National Center for Medical Intelligence (NMCI), and the Bill and Melinda Gates Foundation.
If you are developing an antibiotic or provide solutions to develop antibiotics, prevent spread of AMR, monitor it in real time or have alternative ways to fund antibiotic R&D, don’t miss out. Be sure to join us at the World AMR Congress this October.